Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of MCLA-145 in advanced or metastatic malignancies
NL-OMON54744Phase 1Recruiting
- Sponsor
- Merus
- Start
- Apr 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of MCLA-145 in melanoma, head and neck squamous cell carcinoma (HNSCC), transitional cell carcinoma (TCC) and 5 more (2 arms), sponsored by Merus. Primary endpoints: Safety and tolerability, Dose-limiting toxicities and 1 more. Started Apr 2022; status: recruiting.
02
Drugs
MCLA-145
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)transitional cell carcinoma (TCC)non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON54744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54744.